A Phase 1b, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of FLQ-101 in Premature Neonates at High Risk of Developing ROP

The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.

开始日期2025-10-01

申办/合作机构

Feliqs Corp.

NCT06618521

/ RecruitingN/AIIT

Effect of Pilates Exercise Versus Circuit Exercise Training on Gestational Hypertension

The purpose of the study is to investigate the effect of Pilates exercises versus circuit exercise training on blood pressure and lipids in gestational hypertensive women.

开始日期2024-04-30

申办/合作机构

Cairo University

PACTR202409510583842

/ Recruiting临床3期IIT

Blood pressure control with combination antihypertensives in pregnancy: comparison of Labetalol/Nifedipine versus alpha Methyl-dopa/Nifedipine. a randomized clinical trial in Jos University Teaching Hospital, North central Nigeria

开始日期2024-02-19

申办/合作机构-

100 项与甲基多巴相关的临床结果

登录后查看更多信息

100 项与甲基多巴相关的转化医学

登录后查看更多信息

100 项与甲基多巴相关的专利（医药）

登录后查看更多信息

3,023

项与甲基多巴相关的文献（医药）

2025-12-01·International Journal of Pharmaceutics-X

Comparative study of β-cyclodextrin derivatives with amlodipine inclusion complexes for enhanced solubility, drug release, and anticancer activity

Article

作者: Somu, Prathap ; Haldar, Dibyajyoti ; Srinivasan, Ramachandran ; Ahmad, Naushad ; Velu, Kuppu Sakthi ; Mohandoss, Sonaimuthu ; Roy, Prasanta

Amlodipine (AMD), a calcium channel blocker, has become a viable anticancer treatment because of its biological properties. However, its poor water solubility and low bioavailability hinder its physiological activities and therapeutic applications when administered orally. In this study, inclusion complexes (ICs) of AMD with pure cyclodextrins (CDs) and three different CD derivatives, namely hydroxypropyl β-cyclodextrin (HD), methyl-β-cyclodextrin (MD), and sulfobutylether-β-cyclodextrin (SD), were prepared, and their physicochemical and biological properties were compared. The enhanced solubility of AMD:CD IC formation in aqueous media was measured using UV-Vis and fluorescence spectroscopy, and the binding constants were calculated using the Benesi-Hildebrand method. In addition, phase solubility studies confirmed the formation of 1:1 ICs, which followed an A_L-type profile. Among the various CD derivatives, AMD:SD exhibited a high apparent stability constant (K_1:1) of 1447.5 M^-1, indicating a strong affinity between SD and AMD. The AMD:CDs (1:1) ICs were prepared using the co-precipitation method and characterized to identify the functional groups, crystallinity, morphological changes, and thermal stability, which indicated the successful encapsulation of AMD within CDs. Moreover, molecular docking studies confirmed the encapsulation of AMD within CDs with favorable binding energy and stable interactions. Drug release studies showed an initial burst release followed by a sustained release after 20 min, and the release percentage for the AMD:CDs was between 82 and 98 %. Finally, the AMD:CDs ICs exhibited superior cell viability and cellular uptake in HCT-116 cells using the WST-1 assay compared to that of pure AMD and CDs.

2025-08-13·Scientific Reports

Enhancing methyldopa solubility via green supercritical fluid techniques using ethanol co-solvent.

Article

作者: Mohammad, Suleiman Ibrahim ; Ray, Subhashree ; Mayani, Suranjana V ; Singh, Abhayveer ; Ballal, Suhas ; Alotaibi, Hadil Faris ; Abosaoda, Munthar Kadhim ; Vasudevan, Asokan ; Pramanik, Atreyi

The aim of this study is to investigate the solubility of methyldopa in supercritical carbon dioxide. Solubility was examined at temperatures of 338, 328, 318, and 308 K, in both the presence and absence of a co-solvent. Specifically, ethanol was evaluated as a co-solvent. Semi-empirical and empirical approaches, as well as the Peng-Robinson equation, were applied to analyze the experimental data. The mole fraction (solubility) of methyldopa was found to range from 0.078 × 10^-4 (0.21 g/l) to 1.082 × 10^-4 (3.38 g/l) in the binary system and from 0.405 × 10^-4 (1.38 g/l) to 3.143 × 10^-4 (11.33 g/l) as well as from 1.225 × 10^-4 (4.60 g/l) to 8.979 × 10^-4 (34.94 g/l) at 1 and 3 mol % respectively. The findings indicated that incorporating a co-solvent, particularly ethanol, resulted in a substantial enhancement in solubility. The maximum enhancement was recorded in the methyldopa-ethanol-CO₂ system at 12 MPa and 338 K, where the solubility was found to be 15.70 times higher than in pure supercritical carbon dioxide. The models employed for data evaluation exhibited robust correlations with the experimental outcomes. Among these models, the Soltani-Mazloumi model exhibited the strongest correlation with the experimental solubility data.

2025-08-01·BIOMATERIALS

Immunity/metabolism dual-regulation via an acidity-triggered bioorthogonal assembly nanoplatform enhances glioblastoma immunotherapy by targeting CXCL12/CXCR4 and adenosine-A2AR pathways

Article

作者: Wei, Xinhua ; Zhao, Yandong ; Wei, Ruili ; Li, Jiamin ; Li, Tao ; Yang, Ruimeng ; Lai, Shengsheng ; Yuan, Youyong ; Xie, Kunfeng ; Jiang, Xinqing ; Lin, Wanxian

Blocking the C-X-C motif chemokine ligand-12/C-X-C motif chemokine receptor-4 (CXCL12/CXCR4) signal offers the potential to induce immunogenic cell death (ICD) and enhance immunotherapy of glioblastoma (GBM). However, traditional intracellular targeted delivery strategies and adenosine-mediated tumor immunosuppression limit its therapeutic efficacy. Herein, we present an acidity-triggered self-assembly nanoplatform based on bioorthogonal reaction to potentiate GBM immunotherapy through dual regulation of metabolism and immune pathways. AMD3100 (CXCR4 antagonist) and CPI-444 (adenosine 2A receptor inhibitor) were formulated into micelles, denoted as AMD@iNP_DBCO and CPI@iNP_N3, respectively. Upon administration, the pH-sensitive poly(2-azepane ethyl methacrylate) group of AMD@iNP_DBCO responds to the acidic tumor microenvironment, exposing the DBCO moiety, resulting in highly efficient bioorthogonal reaction with azide group on CPI@iNP_N3 to form large-sized aggregates, ensuring extracellular drug release. The combination of AMD3100 and CPI-444 contributes to ICD induction, dendritic cell maturation, and immunosuppressive milieu alleviation by reducing tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells, leading to a robust antitumor response, thereby significantly prolonging survival in orthotopic GBM-bearing mice. Furthermore, the nanoplatform remarkably amplifies immuno-radiotherapy by potently evoking cytotoxic CD8⁺ T cell priming, and synergized with immune checkpoint blockade by delaying CD8⁺ T cell exhaustion. Our work highlights the potential of the in situ assembly nanoplatform tailored for delivery of extracellular-targeted therapeutic agents for boosting GBM immunotherapy.

项与甲基多巴相关的新闻（医药）

2025-07-07

·创鉴汇

拨康视云港交所上市；麦科奥特获超亿元融资 | 一周融资

据创鉴汇不完全统计，上周（6月30日至7月6日）全球医药大健康领域共披露融资事件24起，融资总额超6.4亿美元。上周代谢疾病领域迎来了2起融资。麦科奥特获超亿元D轮支持，致力于研发双功能和多功能特异性多肽药物，目前已经有7条管线进入临床研发阶段。另一家公司Syntis Bio宣布完成3300万美元A轮融资。该公司专注开发口服靶向药，用于治疗肥胖症、糖尿病及罕见病，其药物设计可精准作用于小肠。核心项目SYNT-101是一款每日口服一次的减肥药，通过短暂地阻断小肠上部十二指肠的营养吸收，并将营养物质重定向到小肠下部，从而刺激饱腹感和代谢调节激素的自然分泌。公司同时布局其他代谢疾病药物的研发。眼科药物公司拨康视云在港交所正式上市，募集总额为6.12亿港元。公司拥有多激酶抑制剂（MKI）平台，开发靶向血管生成的小分子药物，治疗涉及异常血管生成或血管分布的眼部适应症。此外公司还拥有抗体药物协同作用平台，聚焦抗体-小分子药物共轭物。目前，拨康视云共有4款药物处于临床阶段，核心管线CBT-001为一款多激酶抑制剂，适用于预防翼状胬肉发展及减少结膜充血，正处于3期临床阶段。另一家眼科新锐FELIQS同期完成900万美元A轮融资。公司专注于开发靶向氧化脂质的小分子疗法。核心管线FLQ-101旨在预防早产儿视网膜病变，这是一种可能导致早产儿失明的疾病。该药物促进生理性视网膜血管生成，并抑制炎症及异常新生血管形成，目前已经获得美国FDA授予快通道资格和孤儿药资格。读者们请星标⭐创鉴汇，第一时间收到推送免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。更多数据内容推荐点击“在看”，分享创鉴汇健康新动态

孤儿药临床3期申请上市快速通道

2025-07-07

·医药观澜

6家创新药公司完成新一轮融资！

根据公开信息，上周（6月30日~7月6日），全球范围内有至少6家致力于创新药研发的新锐公司宣布完成新一轮融资。通过梳理，这些获得资本青睐的新锐公司正在开发的产品包括小分子药物、多肽疗法等，聚焦的疾病领域涵盖了癌症、心血管疾病、肥胖症等代谢性疾病、眼科、自闭症等神经发育障碍疾病等等。麦科奥特融资轮次：D轮融资金额：超亿元7月3日，麦科奥特宣布完成超亿元D轮融资交割。本轮融资由浙商创投旗下临海启泽基金领投，所募集资金将重点用于推动核心管线研发、制剂产业化基地建设等方面，进一步提升麦科奥特在多肽创新药领域的研发能力。麦科奥特于2007年成立，专注于双功能和多功能特异性多肽药物研发，聚焦于心脑血管、代谢类疾病领域。新闻稿介绍，该公司已有7个创新药管线进入临床研发，包括1个临床3期阶段，3个临床2期阶段和3个临床1期阶段。拨康视云融资轮次：IPO融资金额：6.12亿港元7月3日，拨康视云（Cloudbreak Pharma）在港交所正式上市。配发结果显示，拨康视云全球发售6058.2万股股份，占发行完成后总股份的7.22%，其中香港公开发售1211.55万股，国际发售4846.65万股。最终发售价为每股10.10港元，获得款项总额为6.12亿港元，所得款项净额5.22亿港元。拨康视云是一家专注于眼科领域的临床阶段生物科技公司。此次港股IPO由建银国际、华泰国际担任联席保荐人。拨康视云拟将全球发售所得款项用于支持核心产品CBT-001（一款多激酶抑制剂）的持续临床研发活动、搭建生产设施及商业化活动等。同时加速眼科候选药物在全球的临床开发。Syntis Bio融资轮次：A轮融资金额：3300万美元7月1日，生物制药公司Syntis Bio宣布完成3300万美元的超额认购A轮融资，本轮融资由Cerberus Ventures领投。Syntis Bio公司专注于开发针对肥胖、糖尿病和罕见疾病的口服疗法，这些疗法专为在小肠（人体代谢控制、消化和药物吸收的关键部位）发挥靶向活性而设计。其主导项目SYNT-101为用于治疗肥胖的每日一次口服药物，作用原理是短暂地阻断小肠上部十二指肠的营养吸收，并将营养物质重定向到小肠下部，以刺激饱腹感和代谢调节激素（包括GLP-1）的自然分泌。这种被称为“十二指肠营养排除”的机制是胃旁路手术疗效的关键。Syntis Bio公司还在推进针对罕见代谢疾病和肠道相关疾病的治疗组合。FELIQS融资轮次：A轮融资金额：900万美元7月1日，FELIQS宣布完成900万美元A轮融资，本轮融资由一家美国大型制药公司与Beyond Next Ventures共同领投。FELIQS成立于2019年，专注于开发靶向氧化脂质的创新小分子疗法，用于治疗罕见儿童视网膜疾病。本轮融资资金将加速其主导产品FLQ-101的临床开发，该小分子候选药物旨在预防早产儿视网膜病变（ROP，一种可能导致早产儿失明的疾病），通过促进生理性视网膜血管生成，并抑制炎症及异常新生血管形成发挥作用。该产品已经获得美国FDA授予快速通道资格和孤儿药资格。维眸生物融资轮次：D2+轮融资金额：1.4亿元7月1日，瓯海科投公司下属基金温州瓯海湘投一村股权投资合伙企业（有限合伙）完成对维眸生物科技的D2+轮投资。本轮融资总额达1.4亿元，该资金用于多个眼科创新药临床试验推进、临床前管线研发及技术创新平台扩展。维眸生物是一家聚焦眼科治疗领域的临床阶段创新药研发公司，已经推动多个创新药产品进入或即将进入临床阶段，其产品维眸生物VVN461滴眼液获得中国NMPA纳入突破性治疗品种。VVN461是一款强效JAK1免疫调节剂，能够高活性抑制多个炎症细胞因子（cytokine）通路，从而治疗白内障术后炎症。Stalicla融资轮次：战略投资融资金额：200万瑞士法郎6月30日，专注于开发神经疾病新型小分子变构调节剂组合的临床阶段生物医药公司Addex Therapeutics宣布，其主导了对Stalicla的200万瑞士法郎投资。Stalicla专注于神经发育障碍（NDD）的治疗，将利用这笔资金推进其自闭症候选药物组合。Stalicla正准备启动其主导自闭症候选药物STP1及第二个资产的2期临床试验，两者均针对自闭症谱系障碍（ASD）特定亚群患者。Stalicla还在推进其STP7项目（mavoglurant），一种mGluR5负向变构调节剂（NAM）。期待在资本的助力下，更多前沿疗法和技术能够更快惠及患者。参考资料：[1]各公司官网及公开资料版权说明：本文欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

IPO临床3期临床2期

2024-11-04

·Pharmaceutical Technology

FDA grants fast track status to FELIQS’s FLQ-101 to prevent ROP

ROP affected 27,000 premature neonates in the US in 2019. Credit: ANNA GRANT/Shutterstock. The US Food and Drug Administration (FDA) has granted fast track designation to FELIQS’ lead product FLQ-101, for preventing retinopathy of prematurity (ROP). FLQ-101, which can be administered orally or intravenously once daily, aims to enhance the physiological response of vascularisation in the retina and offers protection against inflammation and abnormal neovascularisation. The company is preparing to launch a Phase Ib/II study, named tROPhy-1, in the US and Japan in the first quarter of 2025. The FDA also granted orphan drug designation to FLQ-101 earlier in 2024. FELIQS is preparing to submit an investigational new drug application for its second asset, FLQ-104, to treat intermediate dry age-related macular degeneration (dry-AMD) in the second half of 2025. FELIQS co-founder and CEO Ken-ichiro Kuninobu stated: “This designation will facilitate the review process and give us better access to the FDA which should shorten the clinical development programme timeline and improve the chances of designing and conducting a successful programme. “We are excited that the FDA recognised the unmet medical need in the target population and that FLQ-101 could potentially close this gap. “At FELIQS, we are committed to helping the most vulnerable members of society. This is exemplified by our focus on extremely premature neonates with the FLQ-101 programme, and elderly patients with intermediate dry-AMD with the FLQ-104 programme.” In 2019, ROP affected 27,000 premature neonates in the US and is a leading cause of childhood blindness. Laser photocoagulation and anti-VEGF [vascular endothelial growth factor] therapy – the two current FDA-approved treatments – are both implemented post-development of ROP and carry risks such as retinal detachment and increased risk of intraocular infection. FLQ-101 is still an investigational medicine and has not yet been approved by regulatory authorities.

孤儿药快速通道临床研究

100 项与甲基多巴相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00405	甲基多巴	C02AB	DB00968

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高血压	美国	Merck & Co., Inc.	1962-12-20
高血压	美国	Merck Research Laboratories Massachusetts LLC	1962-12-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
早产儿视网膜病变	临床2期	美国	Feliqs Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01883804 (CTgov)	N/A	1型糖尿病	30	Methyldopa	獵鏇鏇襯製壓繭壓鏇齋(衊廠簾範顧廠糧膚窪窪) = 構積蓋膚鬱鹽網膚壓艱廠構廠壓艱繭醖廠蓋鹹 (淵襯鏇蓋獵製鹽鬱願壓, 104) 更多	-	2018-03-29